Teachers Advisors LLC cut its holdings in Edwards Lifesciences Corp (NYSE:EW) by 9.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 708,740 shares of the medical research company’s stock after selling 74,119 shares during the period. Teachers Advisors LLC owned 0.33% of Edwards Lifesciences worth $79,882,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Cerebellum GP LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $128,000. Resources Investment Advisors Inc. raised its position in shares of Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares during the period. Exane Derivatives raised its position in shares of Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 961 shares during the period. Captrust Financial Advisors bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $204,000. Finally, Diversified Trust Co bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $209,000. Institutional investors and hedge funds own 82.90% of the company’s stock.
In related news, CFO Scott B. Ullem sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, April 4th. The shares were sold at an average price of $137.17, for a total transaction of $3,429,250.00. Following the completion of the transaction, the chief financial officer now directly owns 35,968 shares of the company’s stock, valued at approximately $4,933,730.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $126.69, for a total transaction of $4,155,432.00. Following the transaction, the chief executive officer now directly owns 74,131 shares of the company’s stock, valued at $9,391,656.39. The disclosure for this sale can be found here. Insiders sold a total of 191,603 shares of company stock valued at $25,589,717 over the last three months. Corporate insiders own 2.13% of the company’s stock.
Shares of NYSE:EW traded down $3.40 on Friday, reaching $137.51. The company’s stock had a trading volume of 1,767,811 shares, compared to its average volume of 1,296,813. Edwards Lifesciences Corp has a 52-week low of $92.90 and a 52-week high of $143.22. The stock has a market capitalization of $29,594.44, a P/E ratio of 36.19, a PEG ratio of 2.07 and a beta of 0.58. The company has a quick ratio of 1.41, a current ratio of 1.80 and a debt-to-equity ratio of 0.15.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The business had revenue of $888.50 million during the quarter, compared to analysts’ expectations of $868.45 million. During the same period last year, the company posted $0.75 EPS. The business’s revenue was up 15.7% on a year-over-year basis. analysts expect that Edwards Lifesciences Corp will post 4.52 earnings per share for the current year.
Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday. Cowen restated a “buy” rating and set a $165.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday, March 20th. Guggenheim restated a “buy” rating and set a $162.00 price objective on shares of Edwards Lifesciences in a research report on Friday, February 2nd. JMP Securities raised their target price on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, February 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $155.00 target price on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $144.16.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/edwards-lifesciences-corp-ew-holdings-decreased-by-teachers-advisors-llc.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.